Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2022-12-27 Regulatory Filings
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings
2022-12-27 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding comments on a Registration Statement on Form S-4 filed by JATT Acquisition Corp. It discusses responses to SEC staff comments on the Registration Statement, including tax opinion disclosures and license agreement descriptions. The document references amendments to the Registration Statement and is clearly a correspondence related to regulatory review of a filing, not the filing itself. It does not contain financial statements or substantive financial data but is a regulatory correspondence and response letter. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and compliance documents that do not fit other specific categories.
2022-12-19 English
FORM S-4/A
Merger & Acquisition Classification · 95% confidence The document is a Form S-4 Registration Statement filed with the SEC, which includes a proxy statement and prospectus related to an extraordinary general meeting for a business combination (merger) involving JATT Acquisition Corp and Zura Bio Limited. It details the terms of the merger, share exchanges, financing arrangements, and shareholder meeting information. This type of filing is primarily related to merger and acquisition activity and tender offers, as it involves registration of securities in connection with a business combination and includes detailed merger terms and shareholder voting information. Therefore, the document fits best under the category of Merger & Acquisition filings (MA). The document length and content confirm it is the actual filing, not just an announcement or summary.
2022-12-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 12, 2022, reporting a material definitive agreement and unregistered sales of equity securities related to a business combination between JATT Acquisition Corp and Zura Bio. It includes detailed descriptions of agreements such as the Business Combination Agreement, License Agreement, Equity Grant Agreement, and related securities transactions. The document is a current report disclosing significant corporate events and transactions, not a full annual or quarterly financial report, nor a transcript, presentation, or proxy statement. It is not a certification or a brief announcement but a detailed regulatory filing reporting material events. Therefore, it fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-12-12 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce material events or corporate changes. The content includes details about a Business Combination Agreement, a License Agreement, and an Equity Grant Agreement involving JATT Acquisition Corp and Zura Bio. It discusses private placement of shares, registration rights, lock-up agreements, and forward-looking statements related to the proposed business combination. There are no financial statements or comprehensive financial data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, audit report, or earnings release. It is a regulatory filing announcing material agreements and transactions, consistent with the purpose of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-12-12 English
DEFR14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement filed with the SEC. It specifically mentions it is an amendment to a previously filed proxy statement for an Extraordinary General Meeting of Shareholders. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document is short (1750 characters) and focuses on correcting a detail in the proxy statement, consistent with proxy solicitation materials. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2022-12-07 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.